LOS ANGELES, July 17, 2025 (GLOBE NEWSWIRE) --  RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, announced today that it has completed the acquisition of iCAD, Inc. (NASDAQ: ICAD) (“iCAD”), a global leader in AI-powered breast health solutions. The integration of iCAD's complementary commercial, technology, and regulatory capabilities into DeepHealth advances DeepHealth’s mission to add

Joint effort with global transplant leader aims to personalize immunosuppression and improve transplant outcomes amid new CMS IOTA policy. "We are honored to work together on a potential solution for more personalized immunosuppression management.” — Thomas Klein, PIRCHE Founder and CEO GRUENWALD, GERMANY, July 17, 2025 / EINPresswire.com / -- Today, PIRCHE AG announced its collaboration with Mayo Clinic to develop new digital risk prediction software designed to inform transplant immunosuppress

Eli Lilly and Pfizer launched new services last year meant to give patients easier access to clinicians who can prescribe their drugs. The direct-to-consumer sites, called LillyDirect and PfizerForAll, quickly attracted scrutiny from lawmakers who questioned whether the pharmaceutical giants’ relationships with telehealth startups influenced doctors to prescribe certain treatments and led to inappropriate prescribing. A report out Thursday from a group of US senators sheds light on those relatio

MADISON, Wis., July 17, 2025 /PRNewswire/ -- BrainXell, a leading producer of iPSC-derived human neurons and glia, is proud to announce the continued growth of its executive leadership team with the appointment of Paul Marcus as President, Chief Operating Officer, Chief Financial Officer and Board of Directors. Continue Reading Paul Marcus, BrainXell President, COO & CFO Dr. Su-Chun Zhang, BrainXell's Advising CSO The company also continues to benefit from the scientific leadership of its fou

Global research award celebrates transformative AI solutions in the fields of neuroscience, biochemistry, and climatology. REDWOOD CITY, Calif., July 17, 2025 /PRNewswire/ -- The Tianqiao and Chrissy Chen Institute and the American Association for the Advancement of Science (AAAS) today announced the winners of the inaugural Chen Institute and Science Prize for AI Accelerated Research, a major annual award celebrating innovative uses of AI to accelerate scientific discovery. The three winners s

Bristol Myers Squibb and Pfizer have launched Eliquis 360 Support, a direct-to-patient online program, which offers the blood thinner to U.S. patients at a discount price. Taking a page from Eli Lilly and Novo Nordisk, who have launched online programs to sell their diabetes and obesity drugs directly to patients, Bristol Myers Squibb and Pfizer are doing the same with their megablockbuster blood thinner Eliquis.The drugmakers have established a direct-to-patient online program, Eliquis

Photo: Liv Hospital via FL Communications ISTANBUL, July 17, 2025 (GLOBE NEWSWIRE) -- The “single-center oncology model,” implemented by only a select number of institutions worldwide, is being carried out with advanced technology and artificial intelligence at Liv Hospital. The model brings together all stages of cancer care—diagnosis, treatment, follow-up, and even home-based care—under one roof, with personalized treatment plans guided by multidisciplinary tumor boards and AI-driven

With a positive phase 3 readout, Novartis is planning an FDA approval application for Pluvicto in metastatic hormone-sensitive prostate cancer later in 2025. Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate.The move comes as Novartis’ second-quarter sales of $14 billion met Wall Street’s expectations, growing 12% year over year. Notably, radioligand therapy Pluvicto has “returned to really robust growth,” Novartis CE

COMPANY ANNOUNCEMENT When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company. Read Announcement Summary Company Announcement Date: July 15, 2025 FDA Publish Date: July 17, 2025 Product Type: Medical Devices Reason for Announcement: Recall Reason Description May have been serviced with previously recalled bezel kit assemblies Company Name: Becton, Dickinson and Compa

The FDA’s Oncologic Drugs Advisory Committee on Thursday voted 5-3 against the overall benefit-risk of GSK’s Blenrep as a second-line multiple myeloma treatment in combination with bortezomib and dexamethasone. The committee also voted 7-1 against — with the patient representative as the only vote in favor — the overall benefit-risk of Blenrep in combination with pomalidomide and dexamethasone. FDA officials raised concerns at the meeting and in briefing documents about eye-related toxicities, f